These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32451342)

  • 21. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
    Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y; Hara M
    Expert Opin Drug Saf; 2019 Nov; 18(11):1109-1118. PubMed ID: 31478753
    [No Abstract]   [Full Text] [Related]  

  • 22. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
    Owen RT
    Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.
    Kuriyama A; Tabata H
    Sleep Med Rev; 2017 Oct; 35():1-7. PubMed ID: 28365447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
    MMW Fortschr Med; 2014 Jul; 156(13):74-5. PubMed ID: 25318234
    [No Abstract]   [Full Text] [Related]  

  • 27. Reduced insomnia following short-term administration of suvorexant during aripiprazole once-monthly treatment in a patient with schizophrenia.
    Suzuki H; Hibino H; Inoue Y; Mikami A; Matsumoto H; Mikami K
    Asian J Psychiatr; 2017 Aug; 28():165-166. PubMed ID: 28784378
    [No Abstract]   [Full Text] [Related]  

  • 28. [Highly selective beginning. Associated symptoms and side effects in retrospect].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():107. PubMed ID: 14579499
    [No Abstract]   [Full Text] [Related]  

  • 29. Suvorexant: a novel therapy for the treatment of insomnia.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2014 Oct; 52(10):23-6. PubMed ID: 25291725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suvorexant for the treatment of insomnia in patients with Alzheimer's disease.
    Hamuro A; Honda M; Wakaura Y
    Aust N Z J Psychiatry; 2018 Feb; 52(2):207-208. PubMed ID: 29237271
    [No Abstract]   [Full Text] [Related]  

  • 31. Suvorexant for the Treatment of Insomnia in Adolescents.
    Kawabe K; Horiuchi F; Ochi M; Nishimoto K; Ueno SI; Oka Y
    J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):792-795. PubMed ID: 28520464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2014 Dec; 68(12):1429-41. PubMed ID: 25231363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of a new thienodiazepine (We-941) on sleep patterns of normal and insomniac subjects.
    Velasco M; Velasco F; Cepeda C; Romo R; Pérez-Toledo MA
    Neuropharmacology; 1981 May; 20(5):461-8. PubMed ID: 7017450
    [No Abstract]   [Full Text] [Related]  

  • 34. Benefits of switching to suvorexant for mild primary insomnia when sleepwalking episodes occur during zolpidem treatment.
    Suzuki H; Hibino H; Inoue Y; Mikami A; Matsumoto H; Mikami K
    Asian J Psychiatr; 2017 Dec; 30():122-123. PubMed ID: 28898806
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of triazolam on the sleep of insomniacs.
    Vogel G; Thurmond A; Gibbons P; Edwards K; Sloan KB; Sexton K
    Psychopharmacologia; 1975; 41(1):65-9. PubMed ID: 164680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
    Herring WJ; Roth T; Krystal AD; Michelson D
    J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits associated with switching from benzodiazepine hypnotics to suvorexant in patients with mild primary insomnia.
    Suzuki H; Hibino H; Inoue Y; Mikami A; Matsumoto H; Mikami K
    Asian J Psychiatr; 2017 Oct; 29():71-72. PubMed ID: 29061431
    [No Abstract]   [Full Text] [Related]  

  • 38. Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts.
    Petrous J; Furmaga K
    BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 29066641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New concepts in the therapy of atrial fibrillation].
    Shin DI; Eckardt L
    Dtsch Med Wochenschr; 2011 Aug; 136(31-32):1587-90. PubMed ID: 21809248
    [No Abstract]   [Full Text] [Related]  

  • 40. Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
    Kishi T; Matsunaga S; Iwata N
    PLoS One; 2015; 10(8):e0136910. PubMed ID: 26317363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.